Sort
48,018 grants matching “immunotherapy”
Lung Cancer Care Outcomes/Surveillance Consortium--Iowa
$460,297University Of Iowa · U01 · FY2001 · CA
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients
$460,204Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients
$460,204Amer Aziz Beg · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Early Detection of Cerebral Amyloid Angiopathy
$460,174Steven M Greenberg · Massachusetts General Hospital · R01 · FY2014 · NS
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer
$460,148Nupam P Mahajan · Washington University · R01 · FY2024 · CA
Computational tumor phenotyping to interrogate treatment resistance and immune dysregulation in head and neck cancer
$460,148Kyle Lafata · Duke University · R01 · FY2025 · CA
In Vivo Analysis of T lymphocytes in the Persistently Infected CNS
$460,102Michael B Oldstone · Scripps Research Institute, The · R01 · FY2010 · AI
APOBEC3 Proteins in HIV Restriction
$460,050Reuben S Harris · University Of Texas Hlth Science Center · R37 · FY2024 · AI
APOBEC3 Proteins in HIV Restriction
$460,050Reuben S Harris · University Of Texas Hlth Science Center · R37 · FY2023 · AI
Programming of CD8+ T Cell Tolerance by B Cell APC
$460,020Stephen Philip Schoenberger · La Jolla Institute For Immunology · R01 · FY2008 · AI
Clinical and Immunological Evaluation of Children with Allergic Disease
$460,018Dean D Metcalfe · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Metabolomics Technologies to Advance Biomedical Research
$460,000Gary E Siuzdak · Scripps Research Institute, The · R35 · FY2025 · GM
Two Compartment Models to Improve Brain Tumor Therapy
$459,957Edward A Neuwelt · Oregon Health & Science University · R01 · FY2012 · CA
Targeting tumor architecture as a novel therapeutic strategy for pancreatic cancer
$459,941Matteo Ligorio · Ut Southwestern Medical Center · R37 · FY2023 · CA
Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy
$459,875Chunru Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
$459,865Eric T Ahrens · University Of California, San Diego · R01 · FY2021 · CA
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
$459,850Laurence J.n. Cooper · University Of Tx Md Anderson Can Ctr · R33 · FY2011 · CA
Duke-UNC Chapel Hill Immunotherapy Training Grant
$459,827Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · T32 · FY2021 · CA
TOLERANCE INDUCTION IN PANCREATIC ISLET TRANSPLANTATION
$459,819Univ Of Massachusetts Med Sch Worcester · R01 · FY2003 · DK
MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY
$459,747University Of Washington · R37 · FY2002 · CA
Understanding CDK1 Function and Cancer Vulnerabilities
$459,739Andrei Goga · University Of California, San Francisco · R01 · FY2024 · CA
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma
$459,722Erinn B Rankin · Stanford University · R01 · FY2025 · CA
An epigenomic approach to reactivate latent HIV
$459,706Qin Feng · University Of Houston · R33 · FY2019 · AI
Developmental Core
$459,685Elizabeth A Klonoff · San Diego State University · U54 · FY2012 · CA
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic disease
$459,683Pooja Jain · Drexel University · R01 · FY2017 · NS